NCT02215044View on ClinicalTrials.gov

Dose-finding Study of BI 2536 Administered in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

December 31, 2008

Conditions
Pancreatic Neoplasms
Interventions
DRUG

BI 2536, intravenous

DRUG

Gemcitabine, intravenous

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY